Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07824323
PHASE4

Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome

Sponsor: Taipei Medical University Hospital

View on ClinicalTrials.gov

Summary

This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of participants with LDL-C below 55 mg/dL at Week 12. Changes in lipid and inflammatory markers, medication adherence, and treatment-emergent adverse events will also be assessed.

Official title: EARLY-BIRD ACS Trial: Early Aggressive Lipid-Lowering Regimen With Bempedoic Acid Initiated for Reducing Dyslipidemia in Patients With Acute Coronary Syndrome

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2026-08-26

Completion Date

2028-12

Last Updated

2026-09-17

Healthy Volunteers

No

Interventions

DRUG

bempedoic acid

Bempedoic acid 180 mg tablet taken orally once daily for 12 weeks.

DRUG

Ezetimibe

Ezetimibe 10 mg tablet taken orally once daily for 12 weeks.

DRUG

High-Intensity Statin Therapy

Atorvastatin 40 mg orally once daily or rosuvastatin 20 mg orally once daily for 12 weeks, selected according to clinical judgment and routine practice.

Locations (1)

Taipei Medical University Hospital

Taipei, Taipei City, Taiwan